Does cognitive impairment in Parkinson’s disease correlate with striatal dopamine transporter scan (DaTscan) uptake?

Mubasher A Qamar1, Anna Sauerbier1, K Ray Chaudhuri1

1Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, King’s College London, UK; National Parkinson Foundation International Center of Excellence, Department of Neurology, King’s College Hospital, London, UK

OBJECTIVE:

Using striatal dopamine transporter scans (DaTscans), we investigate if dopaminergic pathways are responsible for the pathophysiology in cognitive impairment in Parkinson’s disease (PD) patients.

BACKGROUND:

In PD, cognitive impairment can present at early or, more commonly, at late-stages. The pathophysiology has been thought to involve cholinergic dysfunction while the role of dopaminergic dysfunction is unclear. In this study we have explored the dopaminergic basis of cognitive impairment pathophysiology using dopamine transporter scan (DaTscan) imaging in a cohort of PD patients undergoing non-motor assessments.

METHODS:

Patients were enrolled from the Non-motor symptoms International Longitudinal study (NILS). These patients underwent baseline assessments including the Non-motor symptoms (NMS) Scale (NMSS), NMS Questionnaire, as well as other non-motor assessments. A subgroup of these patients also had DaTscan imaging performed. Patient were scanned at optimal ‘ON’ state. Spearman rank correlation coefficient was used to explore the relationship between NMSS scores and the striatal dopaminergic uptake.

RESULTS:

86 patients underwent DaTscan imaging (70.9% male, mean age 62.04 years, mean disease duration 3.0 years, mean age of disease onset 58.86 years). There was no significant correlation between cognitive impairment as measured by attention, concentration, memory and forgetfulness in the NMSS cognitive domain or other measures, with DaTscan uptake in the caudate, putamen or the whole striatum. This is also shown by the mean DaTscan uptake being generally in the normal range.

CONCLUSIONS:

Our data suggests there to be no significant correlation between striatal dopaminergic uptake in patients with cognitive impairment. This suggests dopaminergic pathway is unlikely to be a major pathway involved in cognitive impairment pathophysiology.


ACKNOWLEDGMENTS: We would to thank King’s College Hospital Imaging department including Dr Gill Vivan, Dr N Mulholland, Mr B Cocoran. We would also like to thank Dr Marios Politis and the Neurodegeneration Imaging Group at the Maurice Wohl Clinical Neuroscience Institute, King’s College London, UK.